Colorectal cancer

T cells
#Adagene #Collaboration #Colorectal cancer #Oncology #T cell engagers #Third Arc Bio

Adagene and Third Arc Bio collaborate on masked CD3 T cell engagers

Under a new agreement, Third Arc Bio will utilise Adagene’s SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumour associated antigens.   In return, Third Arc Bio will receive rights to research, develop and commercialise two candidate molecules worldwide.   Adagene will receive an upfront payment of $5… Read More

#Business & Investment #News

Colon cancer
#Colorectal cancer #Larkspur Biosciences #Oncology #Preclinical development #Solid tumours

First degrader of lipid kinase PIP4K2C shows promise in colon cancer

Larkspur Biosciences has announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumours.   The announcement was made at ACS Fall 2025, a meeting of the American Chemical Society in Washington,… Read More

#Cancer Research #News

Pancreatic cancer
#Cancer vaccine #Colorectal cancer #Gene mutation #Oncology #Pancreatic cancer #UCLA

Off-the-shelf cancer vaccine shows promise in KRAS-driven cancers

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer.  The study was led in part by investigators at the UCLA Health Jonsson Comprehensive Cancer Center and… Read More

#Cancer Research #Editor's Choice #News

Colorectal cancer
#Cancer drug targets #Colorectal cancer #Oncology #University of Fukui

New molecular insights reveal potential colon cancer targets

New molecular insights into cancer stem cells have highlighted their potential as therapeutic targets.  In a recent study, researchers have revealed how transcription factors CDX1 and CDX2 suppress cancer cell stemness by blocking β-catenin’s ability to activate key genes like LGR5.   Their findings showed that… Read More

#Cancer Research #Editor's Choice #News

Colon cancer
#China #Colorectal cancer #Monoclonal antibodies #Oncology #Pierre Fabre Laboratories

China approval for colorectal cancer combination treatment

The Chinese authorities have granted a marketing authorisation for Pierre Fabre Laboratories’ Braftovi, in combination with cetuximab, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer, after prior systemic therapy.  The approval is based on the Phase III BEACON CRC trial, which demonstrated a significant improvement in overall… Read More

#News #Regulatory

#Colorectal cancer #Funding #Oncology #Start-ups #University of Arizona #University of Dundee

Start-up receives $4m towards ‘one-shot’ cancer drug

A drug discovery company co-founded by researchers at the University of Dundee and the University of Arizona has received $4 million in venture funding.  Branch Therapeutics, founded in November 2024, is a preclinical stage company seeking to develop drugs that are orally bioavailable, well-tolerated, and can treat multiple cancer types. … Read More

#Business & Investment #Cancer Research #News #Start-up Zone

Colorectal cancer
#Artificial intelligence (AI) #Cancer Research Horizons #Colorectal cancer #Multi-omics #Oncology

Partners develop AI tools to personalise colon cancer treatment

Cancer Research Horizons has announced a collaboration with Histofy to develop tools that predict how colorectal cancer patients respond to different treatment options using the multi-modal S:CORT dataset.  As part of the collaboration, Histofy will use digital pathology images, as well as clinical and molecular data, from the S:CORT dataset… Read More

#Business & Investment #Cancer Research #News

X-ray showing colon cancer
#Bowel cancer #Cancer Research UK #Colorectal cancer #Oncology #Personalised medicine

CRUK commits £5.5m to transform bowel cancer treatment

Cancer Research UK and partners have committed £5.5 ($7.1) million in funding to form a world-leading research team tasked with making personalised medicine a reality for people with bowel cancer.  The CRC-STARS initiative will bring together over 40 research experts from across the UK, Spain, Italy and… Read More

#Cancer Research #News

Colorectal cancer
#Barts Institute #Bowel cancer #Colorectal cancer #Immunotherapy #Oncology #The Francis Crick Institute

CD74 level predicts immunotherapy response in bowel cancer

The amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy, new research has revealed.  If integrated into the clinic, the researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, say testing for… Read More

#Cancer Research #News #Trending News

X-ray showing colon cancer
#Colorectal cancer #Janssen #Monoclonal antibodies #Oncology #Phase II trial

Metastatic colon cancer: 49% response for combination therapy

Janssen-Cilag has shared new data from the Phase Ib/II OrigAMI-1 study at the European Society of Medical Oncology (ESMO) 2024 Congress. The results show that amivantamab combined with chemotherapy demonstrated promising antitumour activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who have not… Read More

#Cancer Research #News #Trending News

#Clinical trial #Colorectal cancer #NuCana #Oncology

Colorectal cancer study to be discontinued

NuCana has revealed that the NuTide:323 colorectal cancer study is being discontinued following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee. The Steering Committee believed that the combination of NUC-3373 with leucovorin, irinotecan and bevacizumab (NUFIRI+bev) was unlikely to achieve the study’s… Read More

#News

Genetics
#Colorectal cancer #Genetics / genomics #The Institute of Cancer Research #The University of Manchester #University of Leeds #University of Oxford

Genetic causes of colorectal cancer revealed in new study

A new study has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC), providing unique understanding of its response to treatment. The research was led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the… Read More

#Cancer Research #News

Liver cancer
#Colorectal cancer #ETH Zurich #Liver cancer #Oncology #Tumour microenvironment (TME)

Study reveals how cancer cells metastasise to the liver

Researchers at ETH Zurich in Switzerland have uncovered how colorectal cancer cells colonise the liver. The findings, by Andreas Moor in the Department of Biosystems Science and Engineering and his team, will help to develop treatments with which they hope could hinder the metastatic process. Read More

#Cancer Research #News #Trending News

#Breast cancer #Cancer research #Colorectal cancer #Leukaemia #Lung cancer #Oncology #Pancreatic cancer

New DDW Highlights podcast: 29 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In the same week that it was revealed that breast cancer was the most… Read More

#News